These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16815295)

  • 41. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
    Vikhanskaya F; D'Incalci M; Broggini M
    Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mdm2 binds p73 alpha without targeting degradation.
    Bálint E; Bates S; Vousden KH
    Oncogene; 1999 Jul; 18(27):3923-9. PubMed ID: 10435614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
    Gong JG; Costanzo A; Yang HQ; Melino G; Kaelin WG; Levrero M; Wang JY
    Nature; 1999 Jun; 399(6738):806-9. PubMed ID: 10391249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.
    Ma Y; Yu WD; Hershberger PA; Flynn G; Kong RX; Trump DL; Johnson CS
    Mol Cancer Ther; 2008 Sep; 7(9):3047-55. PubMed ID: 18790784
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.
    Cipriano R; Patton JT; Mayo LD; Jackson MW
    Cell Cycle; 2010 Apr; 9(7):1373-9. PubMed ID: 20305378
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ΔNp73β on cisplatin treatment in colon cancer cells.
    Lööf J; Pfeifer D; Ding Z; Sun XF; Zhang H
    Mol Carcinog; 2012 Aug; 51(8):628-35. PubMed ID: 21837762
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MDM2: life without p53.
    Daujat S; Neel H; Piette J
    Trends Genet; 2001 Aug; 17(8):459-64. PubMed ID: 11485818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.
    Nieto-Rementería N; Pérez-Yarza G; Boyano MD; Apraiz A; Izu R; Díaz-Pérez JL; Asumendi A
    Br J Dermatol; 2009 Mar; 160(3):519-26. PubMed ID: 19067706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
    Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
    Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
    Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
    Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.
    Leão M; Gomes S; Bessa C; Soares J; Raimundo L; Monti P; Fronza G; Pereira C; Saraiva L
    Exp Cell Res; 2015 Jan; 330(1):164-77. PubMed ID: 25265062
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The p53 gene family.
    Kaelin WG
    Oncogene; 1999 Dec; 18(53):7701-5. PubMed ID: 10618710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promoter specificity and stability control of the p53-related protein p73.
    Lee CW; La Thangue NB
    Oncogene; 1999 Jul; 18(29):4171-81. PubMed ID: 10435630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lentivirus-Mediated Overexpression of SIVA-1 Reverses Cisplatin Resistance in Gastric Cancer in vitro.
    Wang XT; Li L; Kong FB; Zhong XG; Mai W
    Cell Biochem Biophys; 2020 Dec; 78(4):455-463. PubMed ID: 32648086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. p53 Regulation: a family affair.
    Haupt Y
    Cell Cycle; 2004 Jul; 3(7):884-5. PubMed ID: 15190198
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins.
    Roth J; König C; Wienzek S; Weigel S; Ristea S; Dobbelstein M
    J Virol; 1998 Nov; 72(11):8510-6. PubMed ID: 9765388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes.
    Wakasugi T; Izumi H; Uchiumi T; Suzuki H; Arao T; Nishio K; Kohno K
    Oncogene; 2007 Aug; 26(36):5194-203. PubMed ID: 17297437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors involved in the cisplatin resistance of KCP‑4 human epidermoid carcinoma cells.
    Oiso S; Takayama Y; Nakazaki R; Matsunaga N; Motooka C; Yamamura A; Ikeda R; Nakamura K; Takeda Y; Kariyazono H
    Oncol Rep; 2014 Feb; 31(2):719-26. PubMed ID: 24317338
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
    Pivonková H; Pecinka P; Cesková P; Fojta M
    FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Much ado about Nutlin.
    Teoh NC
    J Gastroenterol Hepatol; 2011 Feb; 26(2):213-5. PubMed ID: 21261708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.